Average mark-up Total 25,35% 13,7 -1,6% 0,0% 8,5% 13,7 …3).pdf · Kłobucka 23, 02-699 Warszawa...

PEX PharmaSequence Sp. z o.o., ul. Kłobucka 23, 02-699 Warszawa tel. 022-886-47-15, fax. 022-638-21-29 e-mail: [email protected] http://www.pexps.pl

Sąd Rejonowy dla m. st. Warszawy w Warszawie, XIII Wydział Gospodarczy, KRS 0000178089, REGON: 015579675, NIP 9512093564, kapitał zakładowy 1 000 000 zł.

TotalZmiana vs

2018Total

Change vs

2017Total

Change vs

2017Total

Change vs

2017

January 2 968 -1,8% 1 018 3,6% 613 -2,7% 1 312 -5,4%

February

March

April

May

June

July

August

September

October

November

December

2018

Pharmacy market total 1 Rx reimbursed prescriptions 2 Rx nonreimbursed prescriptions 3 Non Rx products 4

Total turnover (PLN million)

Total open market 1 2 968 4,5% 0,0% -1,8% 2 968 -1,8% 33 817 2,5% 6,6%

Rx reimbursed 2 1 018 2,2% 0,0% 3,6% 1 018 3,6% 11 778 0,9% 2,4%

Rx nonreimbursed 3 613 6,4% 0,0% -2,7% 613 -2,7% 7 586 4,5% 7,8%

Non Rx products 4 1 312 4,8% 0,0% -5,4% 1 312 -5,4% 14 166 2,4% 9,2%

Reimbursement

Reimbursement value (PLN mill ion) 729 3,8% 0,0% 5,5% 729 5,5% 8 694 3,3% 7,9%

Reimbursement share In total turnover 24,6% -0,7% 0,0% 7,4% 24,6% 7,4% 25,7% 0,8% 1,3%

Reimbursement share In reimbursed sales 71,5% 2,5% 0,0% 3,4% 71,5% 3,4% 72,4% 1,8% 5,1%

Average price per pack (PLN)

Total 1 18,75 -1,4% 0,0% 8,9% 18,75 8,9% 18,5 0,6% 5,0%

For reimbursed Rx products 2 27,6 -0,5% 0,0% 2,9% 27,6 2,9% 27,9 1,7% 2,6%

For nonreimbursed Rx products 3 24,6 -1,8% 0,0% 6,2% 24,6 6,2% 24,9 1,0% 7,2%

For Non Rx products 4 13,7 -1,6% 0,0% 8,5% 13,7 8,5% 13,0 0,1% 6,0%

Average mark-up

Total 1 25,35% 2,7% 0,0% -2,6% 25,3% -2,6% 25,2% -0,1% -1,0%

For reimbursed Rx products 2 18,2% -1,4% 0,0% -4,2% 18,2% -4,2% 17,7% -4,6% -5,8%

For nonreimbursed Rx products 3 23,9% -2,1% 0,0% -4,6% 23,9% -4,6% 24,7% -0,6% -2,5%

For Non Rx products 4 29,6% 3,7% 0,0% -0,2% 29,6% -0,2% 29,1% -1,2% -2,5%

Average pharmacy

Number of patients in pharmacies 3 810 6,7% 0,0% -8,2% 3 810 -8,2% 42 289 -1,8% -0,7%

Total turnover (PLN thousand) 1 197 4,5% 0,0% -3,0% 197 -3,0% 2 231 1,4% 4,3%

2018Change vs

2018

Change in comparison to ForecastCumulative YTD

January

2018

December

2017

January

2018

January

20172018

Change vs

2017

Change vs

2016

PEX PharmaSequence monthly report - January 2018

Total open market (sell-out report)

- Total pharmacy turnover cumulative in PLN million -

Retail sales in PLN

2


Sąd Rejonowy dla m. st. Warszawy w Warszawie, XIII Wydział Gospodarczy, KRS 0000178089, REGON: 015579675, NIP 9512093564, kapitał zakładowy 1 000 000 zł


Trends

- Total monthly pharmacy sales in PLN million -

- Total monthly sales in an average pharmacy in PLN -

Retail sales in PLN

1 4

3



December

2017YTD'2017

November

2017

December

2016YTD'2016

Value % Value % Value %

Total turnover (thousand PLN)

Total open market 1 197 197 188 9 4,5% 203 -6 -3,0% 203 -6 -3,0%

Rx reimbursed 2 67 67 66 1 2,2% 66 2 2,4% 66 2 2,4%

Rx nonreimbursed 3 41 41 38 2 6,4% 42 -2 -3,9% 42 -2 -3,9%

Non Rx products 4 87 87 83 4 4,8% 93 -6 -6,5% 93 -6 -6,5%

Average price per pack (PLN)

Total 1 18,75 18,7 19,0 -0,3 -1,4% 17,2 2 8,9% 17,2 1,5 8,9%

For reimbursed Rx products 2 27,6 27,6 27,7 -0,1 -0,5% 26,8 1 2,9% 26,8 0,8 2,9%

For nonreimbursed products 3 24,6 24,6 25,1 -0,5 -1,8% 23,2 1 6,2% 23,2 1,4 6,2%

For Non Rx products 4 13,7 13,7 13,9 -0,2 -1,6% 12,6 1 8,5% 12,6 1,1 8,5%

Average mark-up*

Total 1 25,35% 25,35% 24,7% 0,7% 2,7% 26,0% -0,7% -2,6% 26,0% -0,7% -2,6%

For reimbursed Rx products 2 18,2% 18,2% 18,5% -0,3% -1,4% 19,0% -0,8% -4,2% 19,0% -0,8% -4,2%

For nonreimbursed Rx products 3 23,9% 23,9% 24,4% -0,5% -2,1% 25,0% -1,2% -4,6% 25,0% -1,2% -4,6%

For Non Rx products 4 29,6% 29,6% 28,6% 1,1% 3,7% 29,7% -0,1% -0,2% 29,7% -0,1% -0,2%

Number of patients

Total 1 3 810 3 810 3 570 240 6,7% 4 150 -340 -8,2% 4 150 -340 -8,2%

For reimbursed Rx products 2 740 740 690 50 7,2% 790 -50 -6,3% 790 -50 -6,3%

For nonreimbursed Rx products 3 780 780 730 50 6,8% 880 -100 -11,4% 880 -100 -11,4%

For Non Rx products 4 3 210 3 210 2 990 220 7,4% 3 520 -310 -8,8% 3 520 -310 -8,8%

Number of pharmacies - summary

15 103 15 103 15 103 0 0,0% 14 923 180 1,2% 14 923 180 1,2%

Change Change Change


Average pharmacy

- Pharmacies on the open market -

*Values in „Change – value” for average mark-up in percentage points

Retail sales in PLN

4




Price

- Structure of the average retail price -

All amounts are retail open pharmacy sales in PLN Most important terms: 1 Total open pharmacy market sales 2 Total sales of Rx products covered by NHF reimbursement 3 Total sales of Rx products not covered by NHF reimbursement 4 Total sales of products available without prescription, including OTC medicines, food supplements, herbs, patches,

medical devices, etc.

5



- Monthly turnover value forecast (PLN million, retail gross prices) -

PEX PharmaSequence monthly report - January 2018 PEX PharmaSequence commentary

The pharmacy market in January 2018 saw sales reach close to 2 968m PLN. Value of sales compared to January 2017 fell by more than 54m PLN (-1,8%). Compared to December of 2017 sales grew by more than 128m PLN (+4,5%). Compared to the same period of 2017, the non-prescription segment fell by approximately 75m PLN (-5,4%). Sales based on non-reimbursed prescriptions fell by almost 17m (-2,7%) and on reimbursed prescription grew by 35,4m PLN (+3,6%). Compared to the previous month, value of tracked segments was growing. Value of products sold without a prescription grew by close to 60m PLN (+4,8%), value of reimbursed prescriptions was higher by 22m PLN (+2,2%) and of non-reimbursed drugs grew by approximately 37m PLN (+6,4%). Average pharmacy margin for all drugs in January was 25,4% and was smaller by 0,7pp than the margin in the same period of 2017. Compared to December of 2017 the average pharmacy margin grew by 2,7% (+0,7pp.). The average retail drug price in January was 18,75 PLN and was 1,4% smaller than in the previous month, and 8,9% higher than the average price in January of 2017. The average retail price of reimbursed prescriptions was 27,6 PLN (+2,9% vs January 2017), 24,64 PLN for non-reimbursed prescriptions (+6,2% vs January 2017) and 13,7 PLN for products sold without a prescription (+ 8,5% vs January 2017). Drug reimbursement by the National Health Fund in January was in the amount of close to 729m PLN, 5,5% more than in the same period of 2017. The level of patient copayment for reimbursed drugs in January was 28,4%, smaller by 1,3 pp. compared to January 2017. Patient copayment for reimbursed drugs fell by 1,1 pp from December 2017. Forecast: By the end of 2018 sales of the entire pharmaceutical market will amount to close to 34bn PLN, 2,5% more than in 2017. The estimated value of reimbursement will be over to 8,7bn PLN (+3,3% compared to 2017).

6



Knowledge

Data Research

Expertise

Consulting


About us

PEX PharmaSequence is a Polish consulting and research company with its own wide-ranging

resources of market data. We specialize in services for entities operating in the broadly defined

healthcare market.

As a result of numerous projects, carried out over almost 20 years of the company’s operations on

the Polish market, for innovative, generic, and OTC producers, PEX PharmaSequence has gained

unique expertise that allows us to provide our Clients with valuable support.

It is not without significance that our team, comprising 60+ people, has the benefit of experience gained in service companies specializing in the pharma sector, as well as industry experience acquired in local and global pharmaceutical companies. Our expertise and competencies as well as our knowledge of the Polish pharma market enable us to develop proposals and efficiently carry out projects, which offer added value to our Clients’ business decisions.

We would like to hear from you!

Published on the 15th of February 2018, prepared by Błażej Górniak, Marketing Specialist.

www.pexps.pl more info

Ask us a question: [email protected] 22 886 47 15 [email protected]

7



This document has been prepared by PEX PharmaSequence Sp. z o.o. PEX PharmaSequence Sp. z o. o. is not responsible for any potential decisions taken on the basis of this study or their consequences.

This document is copyright protected by PEX PharmaSequence Sp. z o.o. It is intended for internal client (buyer) use only. The client has no right to transfer this paper or make it available to third parties (including publication). The client also has no right to disclose this document or any of the data or information which results from it. The aforementioned concerns both the entire document and any part of it. Citing or quoting (fair use) of this document, any part of it or any data resulting from it, is permitted only with written permission from PEX PharmaSequence Sp. z o.o. , which outlines the goal and extent of the quotations.

PEX PharmaSequence Sp. z o.o.

ul. Kłobucka 23, 02-699 Warszawa

tel.: (+48) 22 886 47 15

fax (+48) 22 638 21 29

[email protected]

Average mark-up Total 25,35% 13,7 -1,6% 0,0% 8,5% 13,7 …3).pdf · Kłobucka 23, 02-699 Warszawa...

Documents

Transcript of Average mark-up Total 25,35% 13,7 -1,6% 0,0% 8,5% 13,7 …3).pdf · Kłobucka 23, 02-699 Warszawa...